
Loading, please wait...

Loading, please wait...

A systematic review and network meta-analysis included 115 randomized controlled trials with more than 30,000 adults with unipolar major depressive disorder. They compared 21 antidepressants used beyond the acute phase, with fluoxetine as the reference drug. The primary outcome was sustained response, defined as continued response at 6 months or longer; 35 head-to-head continuation trials contributed to the primary analysis, 19 of which were rated at high risk of bias. Compared with fluoxetine, escitalopram (OR 1.62; 95% CI 1.21–2.18), agomelatine (OR 1.57; 95% CI 1.08–2.26) and duloxetine (OR 1.40; 95% CI 1.06–1.85) were associated with higher odds of sustained response, while bupropion and reboxetine had lower odds. Escitalopram and duloxetine also had lower all-cause discontinuation than fluoxetine. The authors concluded that antidepressants can differ in their efficacy for achieving sustained response and in their acceptability. Hence, these findings can inform shared decision-making for patients, prescribers and carers, and that more head-to-head comparative studies are needed to provide reliable information about the long-term effects of all licensed antidepressants.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A systematic review and network meta-analysis included 115 randomized controlled trials with more than 30,000 adults with unipolar major depressive disorder. They compared 21 antidepressants used beyond the acute phase, with fluoxetine as the reference drug. The primary outcome was sustained response, defined as continued response at 6 months or longer; 35 head-to-head continuation trials contributed to the primary analysis, 19 of which were rated at high risk of bias. Compared with fluoxetine, escitalopram (OR 1.62; 95% CI 1.21–2.18), agomelatine (OR 1.57; 95% CI 1.08–2.26) and duloxetine (OR 1.40; 95% CI 1.06–1.85) were associated with higher odds of sustained response, while bupropion and reboxetine had lower odds. Escitalopram and duloxetine also had lower all-cause discontinuation than fluoxetine. The authors concluded that antidepressants can differ in their efficacy for achieving sustained response and in their acceptability. Hence, these findings can inform shared decision-making for patients, prescribers and carers, and that more head-to-head comparative studies are needed to provide reliable information about the long-term effects of all licensed antidepressants.
Today

A clinical decision-support framework using health checkup data from 231,683 adults predicts incident obesity with high discrimination (AUROC 0.918). The system integrates temporal survival analysis and risk-factor explanations to prioritize individualized preventive interventions.
Today

A large cohort study demonstrates that fetal growth restriction in a first pregnancy raises maternal cardiovascular risk within five years postpartum, including elevated rates of heart failure, stroke, and myocardial infarction. Clinicians must initiate proactive postpartum screening and cardiovascular prevention.
Yesterday

A multicenter observational study evaluated an 8-week digital health monitoring platform using wearable sensors in ambulatory heart failure. While participants achieved high daily wear-time of 11.7 hours and 80% completion, initial recruitment revealed significant technology-related onboarding barriers.
Today

A paired cadaveric study compared triple and quintuple percutaneous Achilles tendon lengthening. While quintuple hemisection showed numerically greater elongation, differences were not statistically significant.
Yesterday

Diabetic retinopathy remains a leading cause of preventable visual impairment. This review outlines key strategies for screening, systemic risk factor control, advanced diagnostic imaging, and timely specialist referrals within primary and multidisciplinary care models.
Today